Transcatheter Cardiac Pacemaker Market size is estimated to witness considerable growth prospects from 2017 to 2024 due to increasing prevalence of cardiac disorders, growing geriatric population and lifestyle related disorders.
Remarkable increase in the number of cardiac procedures with leadless pacemaker has been observed. It eliminates the serious complications arises with traditional devices, once the implanted leads get infected or wear out. Investment by healthcare providers on technological advancements, increase in the patient lifespan and improvement in the quality of life, high occurrence and mortality rates associated with cardiac conditions and development of innovative pacemakers will further rise the demand for leadless devices.
Implementation of leadless pacemaker in cardiac surgery is increased due to its MRI compatibility, endeavor to enhance and facilitate the process when bradycardic conditions exist. Advancement in transcatheter process coupled with minimally invasive procedure, reduction in the surgical risks and possible complications, government initiatives for enhancing reimbursement policies, shorter implantation procedure and reduced recovery time will uplift the product demand. Additionally, increasing obesity, changing life style, physical inactivity will fuel the industry share in the coming years.
Transcatheter cardiac pacing system determines the slow or irregular heart rhythms (arrhythmias) with single chamber pacemaker system. It provides an alternative to traditional pacing systems by removing the necessity for permanent transvenous leads while offering therapy for bradyarrhythmias. Restriction to single-chamber ventricular pacing will restrain the industry growth.
The FDA regulates the device under the Medical Devices Act. The Centers for Medicare & Medicaid Services (CMS) offers coverage for the Medtronic Micra Transcatheter Pacing System through Coverage with Evidence Development (CED).
Based on position of pacemaker the industry can be segmented into left ventricle and right ventricle. Right ventricle holds major share due to the prevalence of arrhythmias in right ventricle in comparison to left ventricle. Based on end use the industry can be segmented in hospitals and clinics. Hospital segment is likely to lead the industry due to availability of cost-effective cardiac procedure witnessing a lucrative growth over the forecasted period.
U.S. will drive regional transcatheter cardiac pacemaker market share in 2025 due to presence of leading manufacturers namely Medtronic providing affordable products for the procedure. According to National Center for Biotechnology Information, U.S. National Library of Medicine, around 700,000 pacemakers are implanted annually across the globe with more than 250,000 implanted in the United States. Increasing prevalence of hypertrophic cardiomyopathy, about 1 in 500, growing prevalence of hypertension, established healthcare infrastructure, existence of strategic reimbursement structure and large per capita healthcare expenditure will drive the regional industry share.
European transcatheter cardiac pacemaker market will witness tremendous growth due to growing geriatric population and high prevalence of heart rhythm disorder. Growing clinical trials, increase in survival rates for those affected by complex congenital heart disease and favorable growth opportunities for industry players will increase the product demand. Leadless pacemaker is part of a post-market study in the European Union. According to European Heart Journal, around 400 patients per million population every year undergoes cardiac resynchronization therapy in the region.
Indian will grow at fastest rate among the other Asia Pacific countries owing to the presence of specialization in the field of heart care, innovative methods for cardiac treatment and growing need for medical care. The country has become one of the favorite medical tourism destination that provides excellent medical facilities comparable with other western countries, numerous economic government initiatives, more investment opportunities for multinational players will boost the industry growth. In February 2017, Pharmaceuticals and Medical Devices Agency in Japan approved the implementation of Micra that will expand country’s transcatheter cardiac pacemaker market over the coming years.
Mexico transcatheter cardiac pacemaker market will become more competitive owing to presence of skilled cardiac surgeon and increased number of fast, efficient and affordable cardiac procedures. Moreover, availability of high-quality medical care at low cost will further increase the product application.
According to Heart and Stroke Foundation, South Africa, strokes and heart disease are the second leading causes of death in the country, and approximately 11 million South Africans live with hypertension. The availability of advanced healthcare facilities in the Middle East and Africa region has increased over the period.
Some of the players for transcatheter cardiac pacemaker market includes Medtronic, St. Jude Medical, and EBR Systems. New product launches and technology innovations are commonly used strategy by the companies.